RAF1 and cancer: Cardiotoxicity as well as drug resistance are frequent and severe limitations of prolonged treatment with Food and Drug Administration (FDA)-approved drugs that target Raf/MEK/ERK1/2 signaling in cancer [45,46,47,48,49,50,51].